SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables of $653K in Q1 FY2026
Q1 FY2026 net receivables was $653K.
Context
- Net receivables amounted to 0.3% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 431K USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 431K | — |
Net Receivables vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Net receivables amounts to 0.3% of total assets for SGP, versus a peer median of 7.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.07B USD | +6.6% | -0.8% | 6.6% | |
| Jun 2026 | $1.16B USD | +6.6% | +18.9% | 8.4% | |
| Jun 2026 | $138.9M USD | +67.4% | +44.4% | 15.1% | |
| Apr 2026 | $85.69M USD | +100.7% | -6.1% | 19.0% | |
| Mar 2026 | $24.35M USD | -3.5% | +12.9% | 3.3% | |
| Mar 2026 | $22.44M USD | -27.5% | +28.8% | 7.4% | |
| Mar 2026 | $10.6M USD | +12.4% | -13.7% | 9.7% | |
| Mar 2026 | CHF 1.57M CHF | -38.7% | — | 0.6% | |
| Mar 2026 | $1.16M USD | +161.8% | -65.2% | 0.4% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $653K USD | — | — | 0.3% |
| Peer median (excluding SGP) | — | +6.6% | +6.0% | 7.4% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.